Sign In

Wim Van Hecke

CEO icometrix - precision medicine in neurology, time is brain

Wim Van Hecke is a prominent figure in the field of neurology and medical imaging, particularly known for his work with MRI biomarkers. He is the Founder and CEO of icometrix, a company that develops software solutions for analyzing brain MRI and CT scans to assist patients with neurological disorders such as Multiple Sclerosis, Traumatic Brain Injury, Epilepsy, Alzheimer's Disease, and Stroke.1

Van Hecke's educational background includes:

  • PhD in Magnetic Resonance Imaging from the University of Antwerp
  • MSc in NeuroImaging from the University of Antwerp
  • MSc in Applied Sciences with a minor in Business from Ghent University1

His professional experience includes:

  • Visiting Professor at Vrije Universiteit Brussel (September 2019 - Present)
  • CEO of icometrix (March 2017 - Present)
  • Co-Founder of icometrix (January 2011 - Present)
  • Post-Doctoral researcher at Antwerp University Hospital and Leuven University Hospital1

Van Hecke has been instrumental in developing icometrix's FDA-approved and internationally recognized icobrain software, which is used in over 100 hospitals worldwide. The company collaborates with major pharmaceutical and health tech companies, emphasizing the importance of precision medicine in neurology.1

In addition to his role at icometrix, Van Hecke is actively involved in academic research. He is associated with the AIMS research group (Artificial Intelligence supported Modelling in clinical Sciences) at Vrije Universiteit Brussel.3 His research interests include the application of AI in neuroimaging and the development of digital tools for monitoring and managing neurological disorders.24

Highlights

Sep 3 · linkedin

❗️❗️❗️ We are beyond excited and proud to announce the market approval of icobrain aria, the first market-approved solution for monitoring amyloid-related imaging abnormalities (ARIA) in Alzheimer’s disease.

Besides being the only clinically validated #ARIA detection software (Sima et al., 2024), #icobrain aria becomes the first-ever approved solution designed to detect and measure ARIA-E and ARIA-H during the treatment of Alzheimer’s Disease. It enhances radiological reading performance, reduces reading time compared to unassisted ARIA assessments, improves inter-reader agreement for both ARIA-E and ARIA-H, and increases diagnostic accuracy.

icobrain aria has now gained market approval in several key regions, such as Europe, Israel, Japan, Switzerland, and the United Kingdom (currently FDA-pending). “This market approval for icobrain aria is a game-changer and is well timed,” says Prof. Sebastiaan Engelborghs, chair and professor of neurology at the Vrije Universiteit Brussel and its academic hospital (Universitair Ziekenhuis Brussel). “We notice an increasing adoption of the amyloid-targeting therapies in the countries where there is market approval. Having access to a solution such as icobrain aria will only increase the confidence of physicians to prescribe these new treatments safely", he concludes.

Why is this important?

  • The newly available therapies for Alzheimer’s disease have been linked to the development of specific brain abnormalities known as Amyloid-Related Imaging Abnormalities (ARIA), which can lead to severe neurological complications.
  • Although ARIA can be detected through brain MRI scans, the assessment process is highly challenging, time-consuming, and complex for radiologists.
  • icometrix, the leading imaging #AI company in the field of neurology, has developed unique AI-based algorithms named icobrain aria. These algorithms are designed to detect and measure ARIA on brain MRI scans. As a result, icobrain aria provides relevant ARIA measures and a severity assessment for both subtypes: ARIA-E and ARIA-H.
  • icobrain aria has been validated through a unique study, demonstrating significant benefits for radiologists. It enhances radiological reading performance, reduces reading time compared to unassisted ARIA assessments, improves inter-reader agreement for both ARIA-E and ARIA-H severity, and increases diagnostic accuracy.
  • These advantages benefit both general and specialized radiologists.
  • icobrain aria has now gained market approval in several key regions, such as Europe, Japan, Israel, Switzerland, and the United Kingdom.

👉 A link to the press release can be found in the comments. We’re eager to hear your thoughts about this game-changing development! Share your comments and insights below.

#Alzheimers #ARIA #lecanemab #leqembi #donanemab #kisunla #aduhelm #aducanumab #artificialintelligence #AI #MRI #dementia #neuroradiology #neuroimaging #radiology #neurology

Aug 2 · linkedin

I want to sincerely thank all the people who passed by our booth and with whom we met during the Alzheimer's Association® International Conference, #AAIC24 this week in Philadelphia.

🧠 Thanks to all neurologists who are using or are eager to start using our #icobrain reports that support the (early/differential) diagnosis and treatment monitoring of #alzheimersdisease 🧠 Thanks to all patient advocacy groups and scientific societies for your important work and our great conversations. We have the same mission of improving the lives of individuals with Alzheimer's disease and, together with other biomarkers, the icometrix brain #MRI quantification and care coordination solutions are crucial for this. 🧠 Thanks to all scientists and researchers who are developing the next generation solutions that will impact patient care and who are validating the existing solutions and evidence. We can't wait to start all the research collaborations we discussed during the conference. 🧠 Thanks to all biotech and pharmaceutical representatives we met at #AAIC2024. Precision and personalized medicine aren't possible without the treatments you develop. Thanks for trusting the icometrix solutions and advanced imaging biomarkers to impact your clinical trials and real-world studies. 🧠 Thanks to all people with Alzheimer's disease and their caregivers we had the opportunity to meet with. Your stories and experiences are touching, are essential input for our work, and are fueling us to push even harder to impact care. 🧠 Thanks to my wonderful colleagues Rebecca Bartz and Kathy Hampton for your passion, your drive, and your enthusiasm. ❤️

Related Questions

What are Wim Van Hecke's main research interests at Vrije Universiteit Brussel?
How has icometrix's technology impacted the treatment of neurological disorders?
What are some notable achievements of Wim Van Hecke in the field of MRI biomarkers?
How does Wim Van Hecke's background in business influence his approach to healthcare technology?
What collaborations has Wim Van Hecke been involved in at Vrije Universiteit Brussel?
Wim Van Hecke
Wim Van Hecke, photo 1
Wim Van Hecke, photo 2
Add to my network

Location

Antwerp Metropolitan Area